Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Metabolica Health Inc. ('Metabolica' or the 'Company') a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation (the 'Amalgamation Agreement') with Big Fish Acquisition Corp.

不列颠哥伦比亚省温哥华市--（新闻文件公司-2024年2月26日）-Metabolica Health Inc.（“Metabolica”或“公司”）是糖尿病和肥胖症治疗研究前沿的开创性生物技术公司，很高兴宣布与Big Fish收购公司完成合并（“合并协议”）。

('Big Fish'), effective on January 1, 2024, with the resulting amalgamated company, named Metabolica Health Inc. ('Metabolica Health'), continuing the business of Metabolica..

（“Big Fish”），于2024年1月1日生效，合并后的公司名为Metabolica Health Inc.（“Metabolica Health”），继续经营Metabolica业务。。

Pursuant to the terms of the Amalgamation Agreement dated October 30, 2023, Big Fish amalgamated with Metabolica to form Metabolica Health, and the issued shares of each of Metabolica and Big Fish were exchanged for shares of Metabolica Health or otherwise dealt with as follows: (a) each Class A Common share of Metabolica was exchanged for 22.213 common shares of Metabolica Health; and (b) each common share of Big Fish was exchanged for one-half of one common share of Metabolica Health..

根据2023年10月30日的合并协议条款，Big Fish与Metabolica合并形成Metabolica Health，Metabolica和Big Fish各自发行的股份被交换为Metabolica Health的股份，或以其他方式处理如下：（a）Metabolica的a类普通股被交换为Metabolica Health的22.213股普通股；（b）每一份普通的大鱼都可以换取一半的代谢健康。。

Private Placement

私募

Following the successful amalgamation transaction (the 'Transaction'), Metabolica Health is pleased to announce that it is arranging a non-brokered private placement (the 'Offering') of up to 2,500,000 Units, at a price of $0.40 per Unit, for gross proceeds of up to $1,000,000. Each Unit comprises one common share and one non-transferable common share purchase warrant, with each warrant granting the holder the right to purchase an additional common share, at a price of $0.60 per share, for a period of 24 months following the closing of the Offering.

在成功合并交易（“交易”）之后，Metabolica Health很高兴地宣布，它正在安排一项非经纪私人配售（“发行”），最多250万套，价格为每套0.40美元，总收益高达100万美元。每个单位包括一份普通股和一份不可转让普通股认购权证，每份认购权证授予持有人在发售结束后24个月内以每股0.60美元的价格购买额外普通股的权利。

The Units will be offered by way of the 'accredited investor' exemption under National Instrument 45-106 - Prospectus Exemptions and similar exemptions in Canada, and the Units may be sold to offshore jurisdictions and in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended, collectively known as (the 'Qualifying Jurisdictions')..

根据国家文书45-106《招股说明书豁免》和加拿大类似豁免规定，将以“合格投资者”豁免的方式提供这些单位，并且这些单位可以根据《1933年美国证券法》（修订版）登记要求的一项或多项豁免，以私募方式出售给海外司法管辖区和美国，统称为（“合格司法管辖区”）。。

Governance Changes

治理变化

As a result of the amalgamation, the board of Metabolica Health has been restructured and is presently composed of three directors: (i) two Metabolica nominees, namely Dr. Daniel Auld and Dr. Graham Wood, with Dr. Daniel Auld also assuming the role of Chief Executive Officer of the company; and (ii) Mr.

合并后，Metabolica Health董事会进行了重组，目前由三名董事组成：（i）两名Metabolica提名人，即Daniel Auld博士和Graham Wood博士，Daniel Auld博士也担任公司首席执行官；（ii）先生。

Jamie Hyland, as the nominee from Big Fish. Furthermore, Metabolica Health is announcing the appointment of Mr. Scott Jardin, CPA, CGA, as the company's Chief Financial Officer. These strategic moves signify a pivotal moment for Metabolica, reinforcing its commitment to leadership excellence and innovation in the healthcare sector..

杰米·海兰德（JamieHyland），作为《大鱼》的提名者。此外，Metabolica Health宣布任命CGA注册会计师ScottJardin先生为公司首席财务官。这些战略举措标志着Metabolica的关键时刻，强化了其在医疗保健领域卓越领导和创新的承诺。。

Proposed Listing

拟议上市

Metabolica also announces that it is working toward the preparation of a non-offering prospectus with the intention of becoming a 'reporting issuer' in the Province of British Columbia and pursuing a listing of its common shares on the Canadian Securities Exchange ('CSE'). The contemplated listing on the CSE is contingent upon the fulfillment of specific conditions precedent, including, without limitation, the receipt of all requisite regulatory and exchange approvals.

Metabolica还宣布，它正在准备一份非发行招股说明书，旨在成为不列颠哥伦比亚省的“报告发行人”，并寻求其普通股在加拿大证券交易所（“CSE”）上市。计划在CSE上市取决于具体先决条件的满足，包括但不限于收到所有必要的监管和交易所批准。

Metabolica has not filed a prospectus in any jurisdiction, nor has it filed a listing application with the CSE, and there can be no assurance that the company will be successful in becoming a reporting issuer and listing on the CSE..

Metabolica尚未在任何司法管辖区提交招股说明书，也未向CSE提交上市申请，也无法保证该公司将成功成为报告发行人并在CSE上市。。

Daniel Auld, Ph.D., President & CEO of Metabolica Health, expressed enthusiasm about the amalgamation and upcoming initiatives, 'The merger with Big Fish Acquisition Corp. represents a significant milestone for Metabolica Health, and the team and I are excited to embark on the path toward becoming a reporting issuer and listing on the CSE.

Metabolica Health总裁兼首席执行官丹尼尔·奥德（DanielAuld）博士对合并和即将推出的举措表示了热情，“与Big Fish Acquisition Corp.的合并代表了Metabolica Health的一个重要里程碑，我和团队很高兴能够走上成为报告发行人并在CSE上市的道路。

In addition, the launch of the Offering is pivotal in securing the financing necessary to advance our innovative research and development. Owning valuable intellectual property in the fields of diabetes and obesity treatment not only showcases our commitment to scientific excellence but also positions us to make a profound impact on global health.

此外，发行的启动对于确保推进我们创新研发所需的资金至关重要。在糖尿病和肥胖症治疗领域拥有宝贵的知识产权，不仅表明了我们对科学卓越的承诺，而且使我们能够对全球健康产生深远影响。

With the support of our investors and partners, we are poised to take Metabolica Health to the next level, translating groundbreaking research into viable treatments that can significantly improve patients' lives.'.

在投资者和合作伙伴的支持下，我们准备将代谢健康提升到一个新的水平，将开创性的研究转化为可行的治疗方法，可以显着改善患者的生活。

About Metabolica Health Inc.

关于Metabolica Health Inc。

Metabolica Health Inc. is a development-stage biotechnology firm dedicated to discovering and developing novel treatments for diabetes and obesity. Collaborating with leading universities globally, the Company focuses on leveraging products, their derivatives, and mechanisms related to intestinal microbiome metabolism.

Metabolica Health Inc.是一家处于发展阶段的生物技术公司，致力于发现和开发治疗糖尿病和肥胖症的新方法。该公司与全球顶尖大学合作，专注于利用产品及其衍生物以及与肠道微生物代谢相关的机制。

Owning a valuable intellectual property portfolio in this domain underscores Metabolica Health's innovative approach. With the overall type 2 diabetes treatment market projected to reach $77.2 billion by 2027, growing at a CAGR of 6.6% from 2022 to 2027, Metabolica Health is positioned at the forefront of addressing this significant global health challenge.

拥有该领域宝贵的知识产权组合，突显了Metabolica Health的创新方法。预计到2027年，整个2型糖尿病治疗市场将达到772亿美元，2022年至2027年的复合年增长率为6.6%，代谢健康处于应对这一重大全球健康挑战的前沿。

The Company's background research indicates that 4-cresol, a compound produced by the gut microbiome, holds promise as a therapeutic strategy for diabetes treatment, evidenced by its ability to improve glycemic homeostasis and insulin secretory response in animal models.[1].

该公司的背景研究表明，由肠道微生物组产生的化合物4-甲酚有望成为糖尿病治疗的治疗策略，其改善动物模型中血糖稳态和胰岛素分泌反应的能力证明了这一点。[1] 。

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the '1933 Act') or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the 1933 Act and applicable state securities requirements or pursuant to exemptions therefrom.

本文所述证券尚未也不会根据经修订的《1933年美国证券法》（“1933年法案”）或任何州证券法进行登记，因此，除非符合《1933年法案》的登记要求和适用的州证券要求或根据豁免规定，否则不得在美国境内发售或出售。

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America..

本新闻稿不构成出售要约或招揽购买要约，也不构成在任何司法管辖区内出售任何证券（包括美国境内的任何证券）的行为。。

Additional information on Metabolica Health is available at www.metabolicahealth.com.

有关代谢健康的其他信息，请访问www.metabolicahealth.com。

ON BEHALF OF THE BOARD OF DIRECTORS

代表董事会

'Dan Auld'

“Dan Auld”

Daniel Auld, Ph.D.

Daniel Auld博士。

President & CEO, Director

总裁兼首席执行官、董事

For further information, please contact:

欲了解更多信息，请联系：

Jamie Hyland, B.Comm.

Jamie Hyland，B.Comm。

Director

董事

Metabolica Health Inc.

Metabolica Health公司。

Phone: +1 604.442.2425

电话：+1604.442.2425

Email: jamie@metabolicahealth.com

电子邮件jamie@metabolicahealth.com

Dan Auld

Dan Auld

President & CEO, Director

总裁兼首席执行官、董事

Metabolica Health Inc.

Metabolica Health公司。

Email: dan@metabolicahealth.com

电子邮件：dan@metabolicahealth.com

Edward Ierfino

爱德华·伊尔菲诺

Phone: +1 514.562.1374

电话：+1 514.562.1374

Email: edward@metabolicahealth.com

电子邮件：edward@metabolicahealth.com

Forward-Looking Statements

前瞻性声明

This news release contains 'forward-looking statements' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as 'may', 'will', 'expect', 'likely', 'should', 'would', 'plan', 'anticipate', 'intend', 'potential', 'proposed', 'estimate', 'believe' or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions 'may' or 'will' happen, or by discussions of strategy.

本新闻稿包含适用证券法意义上的“前瞻性声明”。此处包含的所有不具有明确历史性质的声明可能构成前瞻性声明。在某些情况下，前瞻性陈述可以通过单词或短语来识别，例如“可能”，“将”，“期望”，“可能”，“应该”，“将”，“计划”，“预期”，“打算”，“潜在”，“提议”，“估计”，“相信”或这些术语的否定词，或其他类似的单词，表达和语法变化，或某些事件或条件“可能”或“将”发生的陈述，或者通过战略讨论。

Readers are cautioned to consider these and other factors, uncertainties. and potential events carefully and not to put undue reliance on forward-looking statements. Such statements may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter.

提醒读者考虑这些因素和其他不确定性因素。谨慎对待潜在事件，不要过度依赖前瞻性陈述。这些陈述可能被证明是不正确的，实际结果可能与预期结果存在重大差异。本新闻稿中包含的前瞻性声明由本警示声明明确限定，并反映了截至本公告之日公司的期望，此后可能会发生变化。

The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of added information, estimates or opinions, future events, or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law..

公司没有义务更新或修改任何前瞻性陈述，无论是由于增加的信息、估计或意见、未来事件或结果或其他原因，也没有义务解释后续实际事件与此类前瞻性信息之间的任何重大差异，除非适用法律要求。。

###

###

[1] Brial F, et al. The Natural Metabolite 4-Cresol Improves Glucose Homeostasis and Enhances β-Cell Function. Cell Rep. 2020 Feb 18;30(7):2306-2320.e5. doi: 10.1016/j.celrep.2020.01.066. PMID: 32075738.

[1] 天然代谢物4-甲酚可改善葡萄糖稳态并增强β细胞功能。Cell Rep.2020年2月18日；30（7）：2306-2320.e5。doi:10.1016/j.celrep.2020.01.066。PMID:32075738。

NOT FOR DISSEMINATION OR DISTRIBUTION INTO THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

不用于向美国或通过美国通讯社传播或分发

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/199296

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/199296